ACADIA Pharmaceuticals Inc. · FWB:DR6

ACADIA Pharmaceuticals Inc. financial statements

ACADIA Pharmaceuticals Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.07B957.8M726.4M517.2M484.1M441.8M339.1M223.8M124.9M17.3M
Cost of revenue89.0M81.8M41.6M10.2M19.1M10.2M11.3M12.4M9.08M3.08M
Gross profit982.5M876.0M684.8M507.1M473.3M431.5M327.7M211.4M115.8M14.3M
Research and development328.8M303.2M351.6M361.6M239.4M319.1M240.4M187.2M149.2M99.3M
Selling, general and administrative548.9M488.4M406.6M369.1M396.0M388.7M325.6M265.8M255.1M186.5M
Operating income104.8M230.8M-73.4M-223.6M-170.4M-286.6M-246.5M-247.4M-292.4M-272.8M
Depreciation and amortization871.0K920.0K1.46M2.03M2.24M1.46M1.29M1.53M1.24M843.0K
EBITDA105.7M231.7M-71.9M-221.6M-168.2M-285.1M-245.3M-245.9M-291.2M-272.0M
Interest expense6.61M6.26M8.54M14.9M000
Income before tax138.9M258.1M-51.0M-213.4M-167.5M-281.0M-234.4M-243.9M-288.3M-270.1M
Income tax-252.1M31.6M10.3M2.53M351.0K611.0K876.0K1.26M1.12M1.34M
Net income391.0M226.5M-61.3M-216.0M-167.9M-281.6M-235.3M-245.2M-289.4M-271.4M
Earnings per share, basic2.321.37-0.37-1.34-1.05-1.79-1.60-1.94-2.36-2.34
Earnings per share, diluted2.301.36-0.37-1.34-1.05-1.79-1.60-1.94-2.36-2.34

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents177.7M319.6M188.7M114.8M147.4M326.0M189.7M134.8M69.4M163.6M
Short-term investments642.0M436.4M250.2M302.0M373.3M305.9M507.7M338.8M271.9M365.4M
Receivables121.5M98.7M98.3M62.2M64.4M48.2M35.8M26.1M17.3M5.90M
Inventory111.4M91.7M40.4M11.6M14.1M9.68M6.34M4.07M5.25M4.17M
Current assets1.06B938.3M616.1M507.9M617.8M717.6M760.3M526.1M373.5M547.9M
Property, plant and equipment7.51M4.21M4.61M6.02M8.05M9.16M3.18M3.31M2.66M3.08M
Goodwill100
Total assets1.56B1.19B749.0M587.8M700.1M782.6M783.2M540.2M384.5M561.2M
Accounts payable10.9M16.2M17.5M12.7M6.88M8.49M7.22M3.17M8.79M3.91M
Current liabilities277.1M394.9M254.3M125.6M96.1M106.0M74.8M59.6M49.0M42.6M
Long-term debt00
Total debt52.2M52.0M57.2M62.0M64.4M49.5M9.79M
Total liabilities336.8M455.0M317.2M187.4M159.2M155.6M84.0M61.1M49.2M42.7M
Shareholders' equity1.23B732.8M431.8M400.4M540.9M627.0M699.1M479.1M335.3M518.4M
Shares outstanding170.3M166.7M164.7M162.1M161.0M159.6M155.3M143.9M124.4M121.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations109.8M157.7M16.7M-114.0M-125.7M-136.2M-151.1M-167.5M-217.8M-208.4M
Capital spending-4.69M-523.0K-50.0K0-1.12M-7.59M-1.13M-2.10M-812.0K-1.51M
Free cash flow105.1M157.2M16.7M-114.0M-126.8M-143.8M-152.3M-169.6M-218.6M-209.9M
Cash from investing-302.6M-30.5M32.0M73.2M-71.1M192.5M-165.8M-71.5M92.5M-261.9M
Cash from financing49.9M6.84M25.1M8.20M18.2M81.0M371.8M306.6M31.2M533.8M
Dividends paid00
Share buybacks18.2M81.0M371.8M306.6M31.2M518.9M
Change in cash-142.8M133.9M73.8M-32.6M-178.6M137.3M54.9M67.7M-94.1M63.5M